Charles Schwab Investment Management Inc Bio Xcel Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $429 Billion
- Q1 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 190,970 shares of BTAI stock, worth $244,441. This represents 0.0% of its overall portfolio holdings.
Number of Shares
190,970
Previous 187,510
1.85%
Holding current value
$244,441
Previous $553,000
2.71%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding BTAI
# of Institutions
77Shares Held
6.6MCall Options Held
85KPut Options Held
221K-
Black Rock Inc. New York, NY1.33MShares$1.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.1MShares$1.41 Million0.0% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN579KShares$741,3290.0% of portfolio
-
State Street Corp Boston, MA465KShares$595,0820.0% of portfolio
-
Geode Capital Management, LLC Boston, MA458KShares$586,1370.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $35.9M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...